Remepy Raises $36M to Take Hybridopa Into Phase III

Remepy has raised a $36M Series A to move its “Hybrid Drug” thesis from an intriguing clinical-stage idea toward a global Phase III test. O.G. Venture Partners and M Ventures, the strategic venture arm of Merck KGaA, led the August 12, 2026 financing.

The round brings Remepy's total capital raised to $62M. The company plans to use the proceeds to expand pharmaceutical co-development partnerships, broaden its drug-plus-software pipeline, and fund Phase III development of Hybridopa, an investigational Parkinson's program expected to begin pivotal work in Q4 2026.

The larger signal is not simply another biotech company financing an expensive trial. Remepy is asking pharmaceutical companies, regulators, clinicians, and investors to treat adaptive software as part of a medicine rather than an app parked beside one, which moves digital health closer to the clinical and economic machinery of pharma.

What Happened

Remepy's Series A was co-led by O.G. Venture Partners and M Ventures, with participation from NFX, Vine Ventures, Qumra Capital, TechAviv, 97212 Ventures, Fresh Fund, PsyMed Ventures, Tadmor Group, Key1 Capital, and IT-Farm Corp. The company did not disclose a valuation, and the official funding announcement said the financing brings total capital raised to $62M.

The historical funding bridge is less tidy than the headline. In 2024, Remepy announced a $10M seed round led by NFX that brought its then-total financing to $15M, while later reporting cited $26M before this Series A. Remepy has not published a complete round-by-round reconciliation, so the honest version is also the useful one: $36M now, $62M total, and no invented middle chapter.

Founded in 2022, Remepy is led by co-founders Dr. Michal Tsur and Or Shoval as co-CEOs, Eran Etam as CTO, and Prof. Amir Amedi as Chief Scientific Officer. The Ramat Gan-based company has approximately 60 employees.

Why Hybrid Drugs Matter

Remepy calls its model Hybrid Drugs because it combines a prescription medicine with a personalized, AI-driven therapeutic protocol delivered through software. The platform is designed to integrate physical, cognitive, behavioral, speech, and related interventions into the treatment plan instead of leaving patients to assemble multidisciplinary care from separate providers, calendars, and apps.

For patients, the promise is more continuous support around a drug that otherwise cannot adapt after it leaves the pharmacy. For pharmaceutical partners, the pitch is more strategic: software may create new clinical differentiation, new intellectual property, and new ways to manage a medicine's lifecycle if the combined product can clear the same evidence and regulatory bars that govern serious therapeutics.

That “if” is doing real work. Digital health has produced plenty of engagement claims and attractive interfaces, but a drug-software combination has to survive clinical validation, quality systems, regulatory review, reimbursement logic, and ordinary human behavior at the same time. Remepy is not trying to win an app-store category; it is trying to enter the prescription model, where the tolerance for vibes drops toward zero.

Hybridopa Moves Toward Phase III

Hybridopa combines immediate-release levodopa/carbidopa with DopApp, Remepy's adaptive digital protocol for Parkinson's disease. The company says the software delivers structured interventions that address motor and non-motor needs alongside pharmacological treatment, but Hybridopa remains investigational and has not been approved by the FDA or another regulatory authority.

The clinical foundation is encouraging but still early. A peer-reviewed Phase IIa pilot in Brain Communications enrolled 41 patients in a three-week randomized, double-blind, placebo-controlled study. Remepy reported a mean 9.7-point improvement on combined MDS-UPDRS Parts I, II, and III for Hybridopa versus 1.95 points for the control group, with 90% of treated participants achieving at least a 5-point improvement.

Those results give the Series A a clear destination, not a guaranteed ending. The pilot was partly funded by Remepy, and the paper discloses company relationships among several authors. A larger global Phase III program will have to show whether the signal holds across more patients, more sites, more time, and the operational grind that turns a promising study into pivotal evidence.

Why the Investor Mix Is Strategic

M Ventures gives this financing a pharmaceutical connection that a standard venture syndicate would not. Its parent, Merck KGaA, already has a strategic collaboration with Remepy to explore Hybrid Drugs across multiple indications, beginning with rare tumors.

That relationship does not validate Remepy's entire platform, but it does put capital, drug-development experience, and a potential co-development channel in the same room. O.G. Venture Partners adds a growth-oriented lead investor, while NFX and other earlier backers are renewing their support as Remepy crosses from category formation into execution-heavy clinical development.

The money will also support expansion beyond Hybridopa. Remepy says it plans to grow its pharmaceutical partnerships and wider pipeline, turning the platform into a repeatable co-development model rather than a one-program experiment. That is where the company's business case becomes larger than Parkinson's disease, and where the complexity gets larger with it.

What the Round Signals

The funding market is showing renewed interest in companies that connect AI and software to regulated clinical outcomes instead of stopping at workflow automation. Remepy sits in a harder lane because its software is intended to influence treatment, which raises the evidence burden but may also create a more defensible product if the model works.

For operators, the lesson is that software does not become healthcare infrastructure because it is personalized or powered by AI. It becomes infrastructure when clinical evidence, regulatory design, delivery, and economics reinforce one another. Remepy's $36M Series A buys the company time and capacity to test that whole system under Phase III pressure.

For investors and pharmaceutical teams, Q4 2026 is the next meaningful marker. The details of Hybridopa's pivotal design, the expansion of Remepy's Merck collaboration, and any additional co-development programs will show whether Hybrid Drugs can become a repeatable category or remain a compelling exception. The Series A has funded the question; the next trial has to earn the answer.